Onconetix, Inc. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Onconetix's Board approved a 1-for-10 reverse stock split effective November 6, 2026, reducing outstanding shares from ~5.9M to ~589K shares. The split does not change authorized shares (250M), par value ($0.00001), or stockholder ownership percentages, except for fractional share holders who receive cash. All options, warrants, and convertible securities will be adjusted proportionally.
Why this rating
Reverse split is routine capital structure adjustment, common for micro-cap stocks. No change to economics, rights, or business operations. No business event occurred.
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.